The bosentan patient registry: Long-term survival in pulmonary arterial hypertension

Internal Medicine Journal

Volumn 41, Issue 3, 2011, Pages 227-234

  Keogh, A ^a   Strange, G ^c   Mcneil, K ^e   Williams, T J ^c   Gabbay, E ^f   Proudman, S ^g   Weintraub, R G ^d   Wlodarczyk, J ^b   Dalton, B ^h  

^a ST VINCENT S HOSPITAL   (Australia)

^b John Wlodarczyk Consulting Services   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e THE PRINCE CHARLES HOSPITAL   (Australia)

^f ROYAL PERTH HOSPITAL   (Australia)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

^h UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Bosentan; Drug registry; Pulmonary arterial hypertension

Indexed keywords

BOSENTAN; PLACEBO; PROSTACYCLIN;

ADULT; AGE DISTRIBUTION; ARTICLE; AUSTRALIA; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT PREFERENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REGISTER; SCLERODERMA; SURVIVAL TIME; TRANSPLANTATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AUSTRALIA; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; SULFONAMIDES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953009253     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.02139.x     Document Type: Article

References (23)

1. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM etal. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-9.
2. Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant 2007; 26: 181-7.
3. Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004; 126: 1452-9.
4. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-37.
5. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464-9.
6. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF etal. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-23.
7. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A etal. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
8. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A etal. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 372-82.
9. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA etal. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170: 1212-17.
10. Denton CP, Pope JE, Peter HH, Gabrielli A, Boonstra A, van den Hoogen FH etal. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 2008; 67: 1222-8.
11. Galie N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T etal. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 1380-6.
12. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007; 30: 338-44.
13. Wlodarczyk J, Cleland LG, Keogh AM, McNeil KD, Perl K, Weintraub RG etal. Public funding of bosentan for the treatment of pulmonary arterial hypertension in Australia: cost effectiveness and risk sharing. Pharmacoeconomics 2006; 24: 903-15.
14. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N etal. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-9.
15. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589-95.
16. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989-93.
17. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP etal. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92: 926-32.
18. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65: 1336-40.
19. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V etal. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-30.
20. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM etal. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-23.
21. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361: 1533-44.
22. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Heart 2008; 94 (Suppl 1): i1-41.
23. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-50.